FDA Denies Expanded Use of Vascepa

The panel voted 9-2 against approval of the drug until further study
Oct. 18, 2013

Amarin Corporation's triglyceride-lowering drug Vascepa will not be approved for use in a broader patient population until results from an additional study have been analyzed, according to an advisory panel to the U.S. FDA. The panel voted 9-2 against approval of the drug for patients who also take a cholesterol-lowering statin such as Pfizer Inc.'s Lipitor and are at high risk of coronary heart disease. Read the full story

Sign up for Pharma Manufacturing Newsletters
Get the latest news and updates